SBIR/STTR Research Award

Development of Transporter Targeted Platinum Drugs for Glioblastoma

Award identifier eb81e94b92af766450959b547507703c0f8dce52e5e37109c32a789d1f3886b3Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$216,990

Program and phase

SBIR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Apricity Therapeutics
Proposal award date
2016-09-07
Contract end date
2018-09-06
UEI
H6EANYTE9RY1
Solicitation number
PA15-269
Topic code
102

Research abstract

DESCRIPTION provided by applicant The blood brain barrier BBB the restrictive endothelium of the vasculature in the brain represents a major challenge for the development of drugs to treat disorders of the Central Nervous System CNS In particular many drugs cannot enter the brain because they are not able to cross the BBB However influx transporters in the BBB which facilitate the entry of essential nutrients and various endogenous molecules can be harnessed to deliver drugs to the brain Using knowledge of the transporters in the BBB we designed influx transporter targeted anti cancer drugs to treat an important and aggressive human cancer glioblastoma GB GB is the most malignant form of brain cancer that involves glial cells Overall the incidence is rare with people diagnosed in the US each year Platinum drugs are highly effective anti cancer drugs however have had limited use in cancers of the brain because of their inability to cross the BBB Preliminary studies suggest that our lead transporter targeted compound AT is highly potent in GB cell lines The major goal of this SBIR Phase I research is to establish proof of concept that the analogs form DNA adducts are dependent on transporters to enter the brain and the tumor and are efficacious in GB xenograft mouse models Two aims are proposed In studies under the first aim we will determine the potency of AT and a back up analog AT and measure the DNA adduct formation in ten GB cell lines with low and high grades of aggressiveness In the second aim we will establish efficacy in xenograft models of GB and determine the identity of the transporters that mediate the delivery of the compounds across the BBB The proposed studies will confer high commercialization potential for the two lead compounds since both analogs will be poised for critical Investigational New Drug IND enabling studies PUBLIC HEALTH RELEVANCE The proposed research focuses on the development of a new medicine for the treatment of a life threatening brain tumor glioblastoma If successful this research will lead to the development of a highly effective drug that is targeted to glioblastoma and designed to enter the brain The development of this medication will make an enormous contribution to the treatment of one of the most aggressive solid tumors in adults

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

7 SBIR/STTR records share this UEI (2012–2022). Reported award amounts total $1,364,462. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.